Home

Loading...

Table of contents

Langerhans cell histiocytosis

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of langerhans cell histiocytosis are prepared by our editorial team based on guidelines from the Histiocyte Society (HS 2022). ...
Show more

Screening and diagnosis

Diagnosis: as per HS 2022 guidelines, suspect LCH in the presence of characteristic clinical/radiologic features, even when histopathologic review is equivocal.
B
Create free account

Diagnostic investigations

Laboratory testing
As per HS 2022 guidelines:
Obtain laboratory tests to assess for liver insufficiency, cytopenias, markers of inflammation (CRP) at diagnosis.
A
Obtain laboratory tests to rule out diabetes insipidus and anterior pituitary function in patients with polyuria/polydipsia or involvement of pituitary/hypothalamus axis on cranial imaging.
A

More topics in this section

  • Diagnostic imaging

  • Pulmonary function testing

  • Echocardiography

  • Right heart catheterization

  • Cholangiopancreatography

Diagnostic procedures

Biopsy: as per HS 2022 guidelines, perform a biopsy of lesional tissue even in circumstances of highly suggestive clinical and imaging features to confirm LCH diagnosis and to establish BRAF or other MAPK-ERK pathway mutational status.
A
Show 5 more

More topics in this section

  • Mutational analysis

Medical management

Management of unifocal LCH: as per HS 2022 guidelines, offer observation or local therapies, such as surgical excision, intralesional corticosteroids, or radiation, as first-line treatments in patients with unifocal LCH (except diabetes insipidus).
B
Show 2 more

More topics in this section

  • Management of pulmonary LCH

  • Management of multifocal LCH

Follow-up and surveillance

Assessment of treatment response
As per HS 2022 guidelines:
Decide on the type and frequency of response assessments and follow-up examinations depending on the degree of involvement with LCH.
A
Obtain repeated FDG-FDG PET-based imaging study for assessment of disease response after 2-3 months of initiation of therapy in patients with initially FDG-FDG PET-avid LCH. Decide on subsequent imaging frequency individually based on specific clinical scenario.
A